Portola Pharmaceuticals Company Profile (NASDAQ:PTLA)

About Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals logoPortola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PTLA
  • CUSIP: N/A
  • Web: www.portola.com
Capitalization:
  • Market Cap: $2.09 billion
  • Outstanding Shares: 57,020,000
Average Prices:
  • 50 Day Moving Avg: $39.02
  • 200 Day Moving Avg: $30.45
  • 52 Week Range: $15.68 - $42.74
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.16
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $32.37 million
  • Price / Sales: 64.68
  • Book Value: $2.84 per share
  • Price / Book: 12.93
Profitability:
  • EBIDTA: ($242,850,000.00)
  • Net Margins: -1,072.67%
  • Return on Equity: -82.19%
  • Return on Assets: -66.51%
Debt:
  • Current Ratio: 6.36%
  • Quick Ratio: 6.36%
Misc:
  • Average Volume: 852,816 shs.
  • Beta: 1.24
  • Short Ratio: 4
 

Frequently Asked Questions for Portola Pharmaceuticals (NASDAQ:PTLA)

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals Inc (NASDAQ:PTLA) released its quarterly earnings data on Monday, May, 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.46. The company earned $5.12 million during the quarter, compared to the consensus estimate of $4.21 million. Portola Pharmaceuticals had a negative net margin of 1,072.67% and a negative return on equity of 82.19%. Portola Pharmaceuticals's revenue for the quarter was down 37.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.15) earnings per share. View Portola Pharmaceuticals' Earnings History.

Where is Portola Pharmaceuticals' stock going? Where will Portola Pharmaceuticals' stock price be in 2017?

7 analysts have issued twelve-month price objectives for Portola Pharmaceuticals' stock. Their predictions range from $27.00 to $51.00. On average, they anticipate Portola Pharmaceuticals' stock price to reach $40.83 in the next year. View Analyst Ratings for Portola Pharmaceuticals.

What are analysts saying about Portola Pharmaceuticals stock?

Here are some recent quotes from research analysts about Portola Pharmaceuticals stock:

  • 1. Cowen and Company analysts commented, "Portola hosted an investor event at the American College of Cardiology (ACC) annual meeting. Data from betrixaban's APEX Phase III and AndexXa's ANNEXA-4 Phase IV trials were discussed. Investors were keenly focused on examining the APEX clinical data ahead of betrixaban's June PDUFA. While risk remains, we think approval is more likely than not. We remain at Outperform." (3/20/2017)
  • 2. According to Zacks Investment Research, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. " (1/18/2017)

Who are some of Portola Pharmaceuticals' key competitors?

Who owns Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (9.61%), Vanguard Group Inc. (8.16%), BlackRock Inc. (7.13%), FMR LLC (6.90%), State Street Corp (3.49%) and JPMorgan Chase & Co. (1.88%). Company insiders that own Portola Pharmaceuticals stock include Charles J Homcy, Fullerton Management Pte Ltd, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals.

Who sold Portola Pharmaceuticals stock? Who is selling Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Emerald Advisers Inc. PA, UBS Group AG, JPMorgan Chase & Co., Emerald Mutual Fund Advisers Trust, Wellington Management Group LLP, Prudential Financial Inc. and Pictet Asset Management Ltd.. Company insiders that have sold Portola Pharmaceuticals stock in the last year include Charles J Homcy, Mardi Dier, Tao Fu and William Lis. View Insider Buying and Selling for Portola Pharmaceuticals.

Who bought Portola Pharmaceuticals stock? Who is buying Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Bogle Investment Management L P DE, FMR LLC, Vanguard Group Inc., Teachers Advisors LLC, Rosenblum Silverman Sutton S F Inc. CA, UBS Asset Management Americas Inc. and Highbridge Capital Management LLC. View Insider Buying and Selling for Portola Pharmaceuticals.

How do I buy Portola Pharmaceuticals stock?

Shares of Portola Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Portola Pharmaceuticals stock cost?

One share of Portola Pharmaceuticals stock can currently be purchased for approximately $36.72.

Analyst Ratings

Consensus Ratings for Portola Pharmaceuticals (NASDAQ:PTLA) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $40.83 (11.20% upside)

Analysts' Ratings History for Portola Pharmaceuticals (NASDAQ:PTLA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/9/2017Oppenheimer Holdings Inc.Set Price TargetBuy$46.00HighView Rating Details
4/19/2017Citigroup IncSet Price TargetBuy$51.00MediumView Rating Details
3/20/2017Cowen and CompanyBoost Price TargetOutperform$40.00 -> $45.00MediumView Rating Details
3/6/2017Morgan StanleyBoost Price TargetOverweight$31.00 -> $47.00N/AView Rating Details
2/24/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
1/11/2017Goldman Sachs Group IncReiterated RatingNeutral$22.00 -> $27.00N/AView Rating Details
12/27/2016Credit Suisse Group AGBoost Price TargetOutperform$20.00 -> $29.00N/AView Rating Details
3/28/2016William BlairReiterated RatingBuyN/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Portola Pharmaceuticals (NASDAQ:PTLA)
Earnings by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Earnings History by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($1.20)($0.74)$4.21 million$5.12 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.12)($0.95)$3.98 million$13.70 millionViewListenView Earnings Details
11/7/2016Q3($1.10)($1.64)$4.10 million$9.30 millionViewListenView Earnings Details
8/9/2016Q216($1.20)($1.02)$4.38 million$4.23 millionViewListenView Earnings Details
5/5/2016Q1($1.06)($1.15)$7.91 million$8.30 millionViewListenView Earnings Details
2/26/2016Q415($1.12)($1.23)$2.43 million$4.40 millionViewListenView Earnings Details
8/4/2015Q215($1.07)($1.12)$2.30 million$2.39 millionViewListenView Earnings Details
5/6/2015Q115($1.09)($0.95)$2.60 million$2.36 millionViewListenView Earnings Details
3/2/2015Q414($0.90)($0.82)$2.40 million$2.41 millionViewListenView Earnings Details
11/10/2014Q314($0.92)($0.86)$2.73 million$2.40 millionViewListenView Earnings Details
8/6/2014Q214($0.79)($0.76)$2.44 million$2.42 billionViewListenView Earnings Details
5/12/2014Q114($0.72)($0.75)$1.81 million$2.40 millionViewListenView Earnings Details
2/27/2014Q4($0.57)($0.63)$2.17 million$2.10 millionViewListenView Earnings Details
8/15/2013($0.72)($1.47)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Portola Pharmaceuticals (NASDAQ:PTLA)
2017 EPS Consensus Estimate: ($5.38)
2018 EPS Consensus Estimate: ($3.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.30)($1.12)($1.21)
Q2 20172($1.53)($1.06)($1.30)
Q3 20172($1.69)($1.34)($1.52)
Q4 20172($1.58)($1.14)($1.36)
Q1 20181($1.23)($1.23)($1.23)
Q2 20181($1.04)($1.04)($1.04)
Q3 20181($0.74)($0.74)($0.74)
Q4 20181($0.54)($0.54)($0.54)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Portola Pharmaceuticals (NASDAQ:PTLA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Portola Pharmaceuticals (NASDAQ:PTLA)
Insider Ownership Percentage: 4.90%
Institutional Ownership Percentage: 87.38%
Insider Trades by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Insider Trades by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/11/2017William LisCEOSell6,750$36.06$243,405.00View SEC Filing  
4/10/2017Tao FuEVPSell1,097$36.97$40,556.09View SEC Filing  
3/15/2017Charles J. HomcyDirectorSell50,000$40.06$2,003,000.00View SEC Filing  
3/15/2017Mardi DierVPSell10,235$40.02$409,604.70View SEC Filing  
5/2/2016William LisCEOSell5,675$23.86$135,405.50View SEC Filing  
12/9/2015Fullerton Management Pte LtdMajor ShareholderBuy750,000$48.00$36,000,000.00View SEC Filing  
9/18/2015Charles J. HomcyDirectorSell40,067$56.25$2,253,768.75View SEC Filing  
9/18/2015Mardi DierCFOSell8,912$55.00$490,160.00View SEC Filing  
7/15/2015John T CurnutteEVPSell10,000$50.00$500,000.00View SEC Filing  
7/15/2015William LisCEOSell50,000$50.00$2,500,000.00View SEC Filing  
7/13/2015Charles J HomcyDirectorSell50,000$48.00$2,400,000.00View SEC Filing  
7/2/2015William LisCEOSell15,000$45.60$684,000.00View SEC Filing  
7/1/2015William LisCEOSell30,000$45.01$1,350,300.00View SEC Filing  
6/30/2015William LisCEOSell15,000$44.48$667,200.00View SEC Filing  
6/29/2015Charles J HomcyDirectorSell100,000$43.78$4,378,000.00View SEC Filing  
6/22/2015John T CurnutteEVPSell10,000$47.50$475,000.00View SEC Filing  
6/16/2015John T CurnutteEVPSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Mardi DierCFOSell16,119$43.00$693,117.00View SEC Filing  
5/29/2015John T CurnutteEVPSell10,000$42.50$425,000.00View SEC Filing  
5/28/2015John T CurnutteEVPSell10,000$40.30$403,000.00View SEC Filing  
5/27/2015Mardi DierCFOSell6,076$41.00$249,116.00View SEC Filing  
5/12/2015Mardi DierCFOSell13,290$37.88$503,425.20View SEC Filing  
5/11/2015Hollings RentonDirectorSell10,520$38.33$403,231.60View SEC Filing  
5/11/2015Mardi DierCFOSell13,674$38.21$522,483.54View SEC Filing  
4/30/2015William LisCEOSell45,000$35.60$1,602,000.00View SEC Filing  
2/23/2015Charles J HomcyDirectorSell20,000$40.00$800,000.00View SEC Filing  
2/23/2015John T CurnutteEVPSell10,000$40.00$400,000.00View SEC Filing  
2/23/2015Mardi DierCFOSell5,692$39.95$227,395.40View SEC Filing  
2/18/2015John T CurnutteEVPSell10,000$37.50$375,000.00View SEC Filing  
2/17/2015Charles J HomcyDirectorSell20,000$36.00$720,000.00View SEC Filing  
2/17/2015John T CurnutteEVPSell10,000$35.00$350,000.00View SEC Filing  
2/13/2015Charles J HomcyDirectorSell20,000$34.05$681,000.00View SEC Filing  
2/13/2015John T CurnutteEVPSell10,000$32.50$325,000.00View SEC Filing  
1/28/2015Charles J HomcyDirectorSell19,700$30.00$591,000.00View SEC Filing  
1/20/2015William LisCEOSell20,000$27.32$546,400.00View SEC Filing  
1/16/2015William LisCEOSell20,000$26.94$538,800.00View SEC Filing  
11/25/2014Mardi DierCFOSell1,118$28.23$31,561.14View SEC Filing  
11/20/2014William LisCEOSell40,000$26.95$1,078,000.00View SEC Filing  
11/17/2014William LisCEOSell30,000$26.69$800,700.00View SEC Filing  
10/8/2014(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy1,600,000$26.00$41,600,000.00View SEC Filing  
8/25/2014Mardi DierCFOSell5,000$26.26$131,300.00View SEC Filing  
7/25/2014Mardi DierCFOSell5,000$24.11$120,550.00View SEC Filing  
7/3/2014William LisCEOSell30,000$30.41$912,300.00View SEC Filing  
6/30/2014William LisCEOSell10,000$29.23$292,300.00View SEC Filing  
6/25/2014Mardi DierCFOSell5,000$28.52$142,600.00View SEC Filing  
6/18/2014John T CurnutteEVPSell30,000$28.33$849,900.00View SEC Filing  
6/18/2014Mardi DierCFOSell3,706$29.95$110,994.70View SEC Filing  
6/16/2014John T CurnutteEVPSell10,000$26.00$260,000.00View SEC Filing  
6/10/2014Nicholas GalakatosDirectorSell1,369$23.36$31,979.84View SEC Filing  
5/29/2014Mardi DierCFOSell5,000$23.00$115,000.00View SEC Filing  
5/27/2014William LisCEOSell30,000$20.83$624,900.00View SEC Filing  
5/21/2014William LisCEOSell10,000$19.87$198,700.00View SEC Filing  
5/16/2014Jean Jacques BienaimeDirectorSell1,000$22.03$22,030.00View SEC Filing  
4/25/2014Mardi DierCFOSell5,000$24.14$120,700.00View SEC Filing  
3/25/2014Mardi DierCFOSell5,000$25.69$128,450.00View SEC Filing  
10/22/2013Charles J HomcyDirectorSell95,962$23.75$2,279,097.50View SEC Filing  
5/28/2013(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy700,000$14.50$10,150,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Portola Pharmaceuticals (NASDAQ:PTLA)
Latest Headlines for Portola Pharmaceuticals (NASDAQ:PTLA)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Portola Pharmaceuticals, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 6:30 PM
americanbankingnews.com logoPortola Pharmaceuticals Inc (PTLA) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 22 at 4:04 PM
finance.yahoo.com logoPortola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US : May 22, 2017
finance.yahoo.com - May 22 at 9:30 AM
finance.yahoo.com logoPortola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association (EHA)
finance.yahoo.com - May 18 at 9:01 AM
finance.yahoo.com logoETFs with exposure to Portola Pharmaceuticals, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 7:49 PM
americanbankingnews.com logoWilliam Blair Research Analysts Increase Earnings Estimates for Portola Pharmaceuticals Inc (PTLA)
www.americanbankingnews.com - May 11 at 7:52 AM
americanbankingnews.com logoPortola Pharmaceuticals Inc (PTLA) Expected to Post Q2 2017 Earnings of ($1.53) Per Share
www.americanbankingnews.com - May 11 at 7:52 AM
finance.yahoo.com logoPortola Pharmaceuticals, Inc. :PTLA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 11:24 AM
americanbankingnews.com logoPortola Pharmaceuticals Inc (PTLA) Given a $46.00 Price Target by Oppenheimer Holdings Inc. Analysts
www.americanbankingnews.com - May 9 at 11:02 PM
finance.yahoo.com logoPortola Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PTLA) : May 9, 2017
finance.yahoo.com - May 9 at 6:56 PM
globenewswire.com logoPortola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
globenewswire.com - May 9 at 10:57 AM
finance.yahoo.com logoPortola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 10:57 AM
finance.yahoo.com logoPortola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma (ICML)
finance.yahoo.com - May 9 at 10:57 AM
finance.yahoo.com logoEdited Transcript of PTLA earnings conference call or presentation 8-May-17 8:30pm GMT
finance.yahoo.com - May 9 at 10:57 AM
americanbankingnews.com logoPortola Pharmaceuticals Inc (PTLA) Releases Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - May 8 at 9:24 PM
marketbeat.com logoPortola Pharmaceuticals posts 1Q loss
marketbeat.com - May 8 at 6:21 PM
finance.yahoo.com logoPortola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US : May 8, 2017
finance.yahoo.com - May 8 at 11:55 AM
finance.yahoo.com logoInvestor Network: Portola Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 8 at 11:55 AM
americanbankingnews.com logoPortola Pharmaceuticals (PTLA) Receiving Somewhat Favorable Press Coverage, Study Shows
www.americanbankingnews.com - May 4 at 1:40 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Portola Pharmaceuticals Inc (PTLA) Will Post Earnings of -$1.20 Per Share
www.americanbankingnews.com - May 3 at 10:16 PM
americanbankingnews.com logoPortola Pharmaceuticals (PTLA) Getting Somewhat Negative Press Coverage, Study Finds
www.americanbankingnews.com - May 1 at 11:21 AM
finance.yahoo.com logoPortola Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Monday, May 8
finance.yahoo.com - May 1 at 11:05 AM
americanbankingnews.com logoSomewhat Favorable News Coverage Very Likely to Impact Portola Pharmaceuticals (PTLA) Stock Price
www.americanbankingnews.com - April 27 at 6:12 PM
nasdaq.com logoCommit To Buy Portola Pharmaceuticals At $30, Earn 33.9% Annualized Using Options
www.nasdaq.com - April 25 at 6:29 PM
americanbankingnews.com logoPortola Pharmaceuticals Inc (PTLA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 25 at 4:28 PM
finance.yahoo.com logoWhy Shares of Portola Pharmaceuticals Are Up Over 60% in 2017
finance.yahoo.com - April 25 at 10:19 AM
americanbankingnews.com logoPortola Pharmaceuticals (PTLA) Earns Media Sentiment Score of 0.33
www.americanbankingnews.com - April 23 at 9:55 AM
americanbankingnews.com logoPortola Pharmaceuticals Inc (PTLA) PT Set at $51.00 by Citigroup Inc
www.americanbankingnews.com - April 22 at 9:36 PM
americanbankingnews.com logoPortola Pharmaceuticals (PTLA) Receives Media Sentiment Rating of 0.31
www.americanbankingnews.com - April 17 at 4:20 PM
americanbankingnews.com logoPortola Pharmaceuticals Inc (PTLA) Short Interest Down 5.1% in March
www.americanbankingnews.com - April 17 at 10:48 AM
americanbankingnews.com logoSomewhat Positive Media Coverage Somewhat Likely to Effect Portola Pharmaceuticals (PTLA) Stock Price
www.americanbankingnews.com - April 14 at 6:51 PM
americanbankingnews.com logoCitigroup Inc Analysts Give Portola Pharmaceuticals Inc (PTLA) a $51.00 Price Target
www.americanbankingnews.com - April 13 at 6:14 PM
nasdaq.com logoAnalysts Predict 11% Gains Ahead For The Holdings of IYH
www.nasdaq.com - April 12 at 1:43 PM
americanbankingnews.com logoTao Fu Sells 1,097 Shares of Portola Pharmaceuticals Inc (PTLA) Stock
www.americanbankingnews.com - April 11 at 8:25 PM
americanbankingnews.com logoWilliam Lis Sells 6,750 Shares of Portola Pharmaceuticals Inc (PTLA) Stock
www.americanbankingnews.com - April 11 at 7:59 PM
finance.yahoo.com logoLosing Money on a Stock? Blame Your Brain
finance.yahoo.com - April 10 at 6:54 PM
nasdaq.com logoNoteworthy Friday Option Activity: PTLA, CSV, SAGE
www.nasdaq.com - April 7 at 7:44 PM
finance.yahoo.com logoETFs with exposure to Portola Pharmaceuticals, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 12:06 PM
americanbankingnews.com logoPortola Pharmaceuticals Inc (PTLA) Given a $51.00 Price Target at Citigroup Inc
www.americanbankingnews.com - April 3 at 1:55 PM
americanbankingnews.com logoPortola Pharmaceuticals Inc (PTLA) Rating Reiterated by Oppenheimer Holdings Inc.
www.americanbankingnews.com - March 25 at 12:25 AM
fool.com logoWhy Portola Pharmaceuticals Stock Is Already Up an Eye-Popping 72% This Year
www.fool.com - March 24 at 8:12 AM
seekingalpha.com logoRisk-Adjusted Valuation Of Portola Pharmaceuticals Shows Significant Upside
seekingalpha.com - March 22 at 8:50 AM
americanbankingnews.com logoVetr Inc. Downgrades Portola Pharmaceuticals Inc (PTLA) to Buy
www.americanbankingnews.com - March 21 at 12:21 AM
americanbankingnews.com logoPortola Pharmaceuticals Inc (PTLA) PT Raised to $45.00
www.americanbankingnews.com - March 20 at 12:43 PM
americanbankingnews.com logoMorgan Stanley Boosts Portola Pharmaceuticals Inc (PTLA) Price Target to $47.00
www.americanbankingnews.com - March 12 at 11:27 AM
americanbankingnews.com logoPortola Pharmaceuticals Inc (PTLA) Upgraded by Vetr Inc. to “Hold”
www.americanbankingnews.com - March 9 at 1:27 AM
streetinsider.com logoPortola Pharma (PTLA) Announces Betrixaban and AndexXa Presentations at ACC
www.streetinsider.com - March 8 at 12:17 AM
us.rd.yahoo.com logoPORTOLA PHARMACEUTICALS INC Financials
us.rd.yahoo.com - March 7 at 7:15 PM
us.rd.yahoo.com logoPortola Pharmaceuticals Announces Betrixaban and AndexXa™ (andexanet alfa) Presentations at ACC.17
us.rd.yahoo.com - March 7 at 7:15 PM
fool.com logoIs Portola Pharmaceuticals Balance Sheet Safe?
www.fool.com - March 7 at 9:37 AM

Social

Chart

Portola Pharmaceuticals (PTLA) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff